Bucillamine: a potent thiol donor with multiple clinical applications

Area of Science:

• Biochemistry
• Pharmacology
• Cardiovascular Research

Background:

• Bucillamine is a cysteine derivative with two thiol groups, acting as a potent glutathione precursor.
• It replenishes endogenous antioxidant defenses against oxidant injury and possesses anti-inflammatory properties.
• While used orally for rheumatoid arthritis, its parenteral efficacy in acute settings is under investigation.

Purpose of the Study:

• To evaluate the protective effects of bucillamine against ischemia-reperfusion injury in myocardial infarction and organ transplantation models.
• To assess the safety and pharmacokinetic profile of intravenous bucillamine in human subjects.
• To determine therapeutic intravenous doses for acute inflammatory conditions.

Main Methods:

• Preclinical studies using a dog model of myocardial infarction (coronary artery occlusion/reperfusion).
• Assessment of liver protection in organ transplantation models following cold ischemia.
• Phase I clinical trials in human volunteers to evaluate safety, pharmacokinetics, and tolerability of intravenous bucillamine.

Main Results:

• Intravenous bucillamine administration during reperfusion significantly reduced myocardial infarct size in a canine model.
• Bucillamine demonstrated marked protection of livers subjected to cold ischemia in transplantation models.
• Phase I human studies showed no serious toxicity at doses up to 25 mg/kg/h intravenously for 3 hours.

Conclusions:

• Parenteral bucillamine shows strong preclinical evidence of efficacy in acute inflammatory and oxidative stress conditions.
• Intravenous bucillamine is a potent thiol donor, superior to N-acetylcysteine, with potential therapeutic applications in myocardial infarction and organ transplantation.
• Pharmacokinetic data suggest effective therapeutic doses for bucillamine infusion in humans for acute inflammatory syndromes.